Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?

@article{Kulpeng2013CostutilityAO,
  title={Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?},
  author={Wantanee Kulpeng and Pattara Leelahavarong and Waranya Rattanavipapong and Vorasith Sornsrivichai and Henry C. Baggett and Aronrag Meeyai and Warunee Punpanich and Yot Teerawattananon},
  journal={Vaccine},
  year={2013},
  volume={31 26},
  pages={2839-47}
}
OBJECTIVE This study aims to evaluate the costs and outcomes of offering the 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) in Thailand compared to the current situation of no PCV vaccination. METHODS Two vaccination schedules were considered: two-dose primary series plus a booster dose (2+1) and three-dose primary series plus a booster dose (3+1). A cost-utility analysis was conducted using a societal perspective. A Markov simulation… CONTINUE READING